These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 29220114)

  • 1. Treat-and-extend versus every-other-month regimens with aflibercept in age-related macular degeneration.
    Haga A; Kawaji T; Ideta R; Inomata Y; Tanihara H
    Acta Ophthalmol; 2018 May; 96(3):e393-e398. PubMed ID: 29220114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-Year Outcomes of Treat-and-Extend Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration: A Prospective Study.
    Maruko I; Ogasawara M; Yamamoto A; Itagaki K; Hasegawa T; Arakawa H; Nakayama M; Koizumi H; Okada AA; Sekiryu T; Iida T
    Ophthalmol Retina; 2020 Aug; 4(8):767-776. PubMed ID: 32417356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
    Jørstad ØK; Faber RT; Moe MC
    Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
    Ogasawara M; Koizumi H; Yamamoto A; Itagaki K; Saito M; Maruko I; Okada AA; Iida T; Sekiryu T
    Jpn J Ophthalmol; 2018 Sep; 62(5):584-591. PubMed ID: 29974277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A modified treat-and-extend regimen of aflibercept for treatment-naïve patients with neovascular age-related macular degeneration.
    Ohnaka M; Nagai Y; Sho K; Miki K; Kimura M; Chihara T; Takahashi K
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):657-664. PubMed ID: 27743159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
    Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Ng P; Pecheur FL; McAllister IL
    JAMA Ophthalmol; 2019 Apr; 137(4):372-379. PubMed ID: 30676617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration.
    Matsumoto H; Hiroe T; Morimoto M; Mimura K; Ito A; Akiyama H
    Jpn J Ophthalmol; 2018 Mar; 62(2):144-150. PubMed ID: 29411171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-Year Outcomes of a Treat-and-Extend Regimen Using Intravitreal Aflibercept Injections for Typical Age-Related Macular Degeneration.
    Ito A; Matsumoto H; Morimoto M; Mimura K; Akiyama H
    Ophthalmologica; 2017; 238(4):236-242. PubMed ID: 28898873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration.
    Abdin AD; Suffo S; Asi F; Langenbucher A; Seitz B
    Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1671-1677. PubMed ID: 31144055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration.
    Saito M; Kano M; Itagaki K; Sekiryu T
    Jpn J Ophthalmol; 2017 Jan; 61(1):74-83. PubMed ID: 27660164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SHORT-TERM SAFETY OF 2 MG INTRAVITREAL ZIV-AFLIBERCEPT.
    Chhablani J; Dedhia CJ; Peguda HK; Stewart M
    Retina; 2017 Oct; 37(10):1859-1865. PubMed ID: 28060148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration.
    Kvannli L; Krohn J
    Acta Ophthalmol; 2017 Nov; 95(7):678-682. PubMed ID: 28139082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Kim JH; Kim CG; Lee DW; Yoo SJ; Lew YJ; Cho HJ; Kim JY; Lee SH; Kim JW
    Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):107-116. PubMed ID: 31741044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-frequency aflibercept injections in persistent neovascular age-related macular degeneration.
    Muftuoglu IK; Tsai FF; Gaber R; Alam M; Meshi A; Freeman WR
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):709-717. PubMed ID: 27878592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of switching to aflibercept for treatment-resistant neovascular age-related macular degeneration.
    Spooner K; Hong T; Nair R; Chow NCC; Broadhead GK; Wijeyakumar W; Chang AA
    Acta Ophthalmol; 2019 Aug; 97(5):e706-e712. PubMed ID: 30740921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration.
    Braimah IZ; Agarwal K; Mansour A; Chhablani J;
    Br J Ophthalmol; 2018 Jan; 102(1):91-96. PubMed ID: 28596286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration.
    Zhu M; Wijeyakumar W; Syed AR; Joachim N; Hong T; Broadhead GK; Li H; Luo K; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):475-484. PubMed ID: 27572301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration.
    Almuhtaseb H; Kanavati S; Rufai SR; Lotery AJ
    Eye (Lond); 2017 Jun; 31(6):878-883. PubMed ID: 28186507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Age-Related Macular Degeneration (AMD) in the Fellow Eye of Patients with AMD Treated by Treat-and-Extend Intravitreal Therapy with Aflibercept.
    Mimura K; Matsumoto H; Morimoto M; Akiyama H
    Ophthalmologica; 2018; 239(2-3):121-127. PubMed ID: 29169154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.
    Morimoto M; Matsumoto H; Mimura K; Akiyama H
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1891-1897. PubMed ID: 28669041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.